IV NEWS
Events and training - March 11, 2024
Scientific evidence on VATs: Is there enough? Is it robust?
There is much scientific evidence available on the efficacy of vascular access teams (VATs) in managing costs, preventing intravenous (IV)…
Events and training February 19, 2024
How to turn a PICC team into a vascular access team
On the second day of BD MACOV@23, a virtual edition of the Multidisciplinary Advanced Course on Vascular Access (MACOVA) held…
“Complications of IV catheter therapy are simply the result of one complex and highly variable mechanical system—IV catheter equipment design,...
News and innovation February 12, 2024
Best practices for phase 1 investigational drugs trials
Before pharmaceutical products are released onto the market, they undergo extensive screening as an investigational drug (IND, or investigational new…
News and innovation February 5, 2024
Key insights on recent amendments to EU-MDR
The European Medical Device Regulation (EU-MDR) 2017/745 has brought many changes to the medical device industry and product availability. Thanks…
Events and training February 1, 2024
PICC line or port catheter: Which one for cancer patients?
It can be challenging knowing when to insert a peripherally inserted central catheter (PICC line) or port catheter into patients…
News and innovation January 22, 2024
Quality control of prefilled flush syringes: key considerations
Before delving into the quality control of prefilled flush syringes, which are an integral part of vascular access management (VAM),…
News and innovation January 15, 2024
Antibiotics shortages in Europe: what you need to know
“A new approach is needed to better tackle medicines shortages in the European Health Union,” the European Commission said in…
Fast fact
TIVA anaesthesia
Propofol-based total intravenous anaesthesia (TIVA) emits four orders of magnitude less greenhouse gases than inhaled anaesthesia with desflurane and N2O.